Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27899802 | 0.92 | MAPT (0.54) | CYP19A1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL27899787 | 0.91 | MEN1 (0.50) | CYP19A1CNR2KDM4EKMT2AMEN1 | |
| SCHEMBL25189259 | 0.88 | CCR9 (0.49) | CYP19A1CNR2KDM4EMAPTHDAC6 | |
| SCHEMBL4169127 | 0.87 | CYP19A1 (0.51) | CYP19A1P2RX4CNR2KDM4EKMT2A | |
| SCHEMBL5850826 | 0.87 | HDAC6 (0.59) | CYP19A1P2RX4CNR2HDAC6HDAC1 | |
| SCHEMBL2214460 | 0.86 | CNR2 (0.55) | CYP19A1P2RX4CNR2KDM4EKMT2A | |
| SCHEMBL2215492 | 0.85 | CNR2 (0.57) | CYP19A1P2RX4CNR2KDM4EKMT2A | |
| SCHEMBL2212614 | 0.85 | CNR2 (0.56) | CNR2KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2214890 | 0.85 | CNR2 (0.46) | CYP19A1CNR2KDM4EKMT2AMEN1 | |
| SCHEMBL2215826 | 0.85 | CNR2 (0.56) | CNR2KDM4EKMT2AALDH1A1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | claimed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | claimed |
| CN-109288838-A | B-carboline -3- carboxylic acid dimer is used to prepare the application for preventing and treating anti-lung-cancer medicament | 西北农林科技大学 | 2019-02-01 | — | — | CN | disclosed |
| CN-102952151-B | 3 double β carbolines alkaloid compounds, its preparation method and its pharmaceutical composition and purposes | 新疆华世丹药物研究有限责任公司 | 2017-07-28 | — | — | CN | disclosed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| CN-101429198-B | Banisterine derivant and uses thereof | XINJIANG HUASHIDAN MEDICAMENTS RES CO LTD | 2013-10-23 | — | — | CN | disclosed |
| CN-102952151-A | 3-position bis-beta-carboline alkali compound, and preparation method, pharmaceutical composition and application thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD | 2013-03-06 | — | — | CN | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | CYP19A1 445/4885P2RX4 1233/4885CNR2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.